NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03615326,Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811),https://clinicaltrials.gov/study/NCT03615326,,ACTIVE_NOT_RECRUITING,"The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).",YES,Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma,BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Placebo|DRUG: Cisplatin|DRUG: 5-FU|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: S-1|BIOLOGICAL: Trastuzumab,"Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR, PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. PFS was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis., Up to 46 months|Overall Survival (OS), OS is defined as the time from randomization to death due to any cause. OS was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis., Up to 63 months","Objective Response Rate (ORR) Per RECIST 1.1 Assessed by BICR, ORR is defined as the percentage of participants who have a Complete Response (\[CR\], disappearance of all evidence of disease) or Partial Response (\[PR\], regression of measurable disease and no new sites) per RECIST 1.1 as assessed by blinded independent central review (BICR). ORR was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis., Up to 63 months|Duration of Response (DOR) Per RECIST 1.1 Assessed by BICR, For participants who demonstrate CR or PR, DOR is defined as the time from first response (CR or PR) to subsequent disease progression or death from any cause, whichever occurs first. DOR was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis., Up to 63 months|Number of Participants Who Experienced an Adverse Event (AE), An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced an AE is reported for each treatment arm. Per statistical analysis plan, data from the second course of pembrolizumab was not included in the safety analysis., Up to 63 months|Number of Participants Who Discontinued Study Treatment Due to AEs, An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued study treatment due to an AE is reported for each treatment arm. Per statistical analysis plan, data from the second course of pembrolizumab was not included in the safety analysis., Up to 63 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,738,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",3475-811|MK-3475-811|184142|2023-508253-98|U1111-1297-9360|2018-000224-34,2018-10-05,2024-03-20,2025-09-17,2018-08-03,2025-03-25,2025-03-25,"UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0045), Los Angeles, California, 90095, United States|Pacific Cancer Care ( Site 0063), Monterey, California, 93940, United States|UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0050), Orange, California, 92868, United States|University of Miami Sylvester Comprehensive Cancer Center - Plantation ( Site 0026), Miami, Florida, 33136, United States|Southeastern Regional Medical Center, Inc. ( Site 0058), Newnan, Georgia, 30265, United States|Midwestern Regional Medical Center, Inc. ( Site 0059), Zion, Illinois, 60099, United States|Beth Israel Deaconess Medical Center ( Site 0070), Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute [Boston, MA] ( Site 0010), Boston, Massachusetts, 02215, United States|Minnesota Oncology Hematology, PA ( Site 8001), Minneapolis, Minnesota, 55404, United States|Washington University School of Medicine ( Site 0040), Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0071), Middletown, New Jersey, 07748, United States|Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0065), Harrison, New York, 10604, United States|Memorial Sloan-Kettering Cancer Center ( Site 0017), New York, New York, 10065, United States|University of Rochester ( Site 0041), Rochester, New York, 14642, United States|Levine Cancer Institute ( Site 0015), Charlotte, North Carolina, 28204, United States|Duke Cancer Institute ( Site 0042), Durham, North Carolina, 27710, United States|CTCA Southwestern ( Site 0060), Tulsa, Oklahoma, 74133, United States|Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, 19124, United States|Allegheny General Hospital ( Site 0053), Pittsburgh, Pennsylvania, 15212, United States|Sanford Hematology Oncology-Sioux Falls SD ( Site 0004), Sioux Falls, South Dakota, 57104, United States|University of Texas MD Anderson Cancer Center ( Site 0001), Houston, Texas, 77030, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8000), Roanoke, Virginia, 24014, United States|Seattle Cancer Care Alliance ( Site 0038), Seattle, Washington, 98109, United States|Liverpool Hospital ( Site 2206), Liverpool, New South Wales, 2170, Australia|Westmead Hospital ( Site 2200), Westmead, New South Wales, 2145, Australia|Southern Medical Day Care Centre ( Site 2207), Wollongong, New South Wales, 2500, Australia|Monash Health ( Site 2202), Clayton, Victoria, 3168, Australia|Hospital Sao Rafael ( Site 0209), Salvador, Bahia, 41253-190, Brazil|Instituto do Cancer do Ceara ( Site 0208), Fortaleza, Ceara, 60430-230, Brazil|CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0205), Curitiba, Parana, 80810-050, Brazil|Hospital de Caridade de Ijui ( Site 0202), Ijui, Rio Grande Do Sul, 98700 000, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0203), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|CEPON - Centro de Pesquisas Oncologicas ( Site 0200), Florianopolis, Santa Catarina, 88034-000, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0201), Rio de Janeiro, 20231-050, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0204), Sao Paulo, 03102-002, Brazil|Centro Investigación del Cáncer James Lind ( Site 0300), Temuco, Araucania, 4780000, Chile|Clinica Universidad Catolica del Maule ( Site 0305), Talca, Maule, 3460000, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0302), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile ( Site 0301), Santiago, Region M. De Santiago, 7620002, Chile|Instituto Nacional del Cancer ( Site 0303), Santiago, Region M. De Santiago, 8380455, Chile|Shanghai General Hospital ( Site 2404), Shanghai, Anhui, 200080, China|Peking Union Medical College Hospital ( Site 2419), Beijing, Beijing, 100032, China|Fifth Medical Center of CPLA General Hospital ( Site 2415), Beijing, Beijing, 100071, China|Beijing Cancer Hospital ( Site 2413), Beijing, Beijing, 100142, China|Fujian Provincial Cancer Hospital ( Site 2418), Fuzhou, Fujian, 350014, China|900 Hospital of the Joint ( Site 2420), Fuzhou, Fujian, 350025, China|The First Affiliated Hospital of Xiamen University ( Site 2431), Xiamen, Fujian, 361003, China|Guangdong General Hospital ( Site 2433), Guangzhou, Guangdong, 510080, China|Harbin Medical University Cancer Hospital ( Site 2407), Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital ( Site 2400), Zhengzhou, Henan, 450008, China|Xiangya Hospital Central-South University ( Site 2426), Changsha, Hunan, 410008, China|Jiangsu Cancer Hospital ( Site 2432), Nanjing, Jiangsu, 210009, China|The First Hospital Of Jilin University ( Site 2402), Chang chun, Jilin, 130021, China|Fudan University Shanghai Cancer Center ( Site 2424), Shanghai, Shanghai, 200032, China|Zhongshan Hospital affiliated to Fudan University ( Site 2401), Shanghai, Shanghai, 200032, China|Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2430), Urumqi, Xinjiang, 830001, China|The First Affiliated Hospital.Zhejiang University ( Site 2408), Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital ( Site 2412), Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital ( Site 2409), Hangzhou, Zhejiang, 310022, China|CHU de Rouen ( Site 0912), Rouen, Ain, 76000, France|HUS Hopital Hautepierre ( Site 0910), Strasbourg, Bas-Rhin, 67098, France|Hopital Jean Minjoz Besancon ( Site 0901), Besancon, Doubs, 25030, France|C.H.R.U. de Brest - Hopital Morvan ( Site 0913), Brest, Finistere, 29200, France|Centre Oscar Lambret ( Site 0911), Lille, Nord, 59000, France|Centre Leon Berard ( Site 0904), Lyon, Rhone, 69008, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0902), Saint-Herblain, Val-de-Marne, 44805, France|Institut Gustave Roussy ( Site 0900), Villejuif, Val-de-Marne, 94805, France|CHU Hopital Saint Antoine ( Site 0905), Paris, 75012, France|SLK-Kliniken Heilbronn ( Site 1015), Heilbronn, Baden-Wurttemberg, 74078, Germany|Klinikum Ludwigsburg ( Site 1014), Ludwigsburg, Baden-Wurttemberg, Germany|Innere Medizin I, Universitaetsklinikum Tuebingen ( Site 1020), Tuebingen, Baden-Wurttemberg, 72076, Germany|Klinikum rechts der Isar der Technischen Universitaet ( Site 1027), Muenchen, Bayern, 81675, Germany|Medizinische Hochschule Hannover ( Site 1019), Hannover, Niedersachsen, 30625, Germany|Universitaetsklinikum Carl Gustav Carus der Technischen Univ ( Site 1001), Dresden, Sachsen, 01307, Germany|Universitaetsklinikum Leipzig AOeR ( Site 1007), Leipzig, Sachsen, 04103, Germany|Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 1026), Berlin, 13353, Germany|Klinikum Bremen Nord ( Site 1017), Bremen, 28211, Germany|Facharztzentrum Eppendorf ( Site 1025), Hamburg, 20249, Germany|Asklepios Klinik Altona ( Site 1000), Hamburg, 22763, Germany|Celan SA ( Site 0504), Guatemala, 01010, Guatemala|Oncomedica ( Site 0500), Guatemala, 01010, Guatemala|Grupo Angeles SA ( Site 0501), Guatemala, 01015, Guatemala|Nucare Center ( Site 0506), Guatemala, 01015, Guatemala|Medi-K Cayala ( Site 0505), Guatemala, 01016, Guatemala|Centro Regional de Sub Especialidades Medicas SA ( Site 0502), Quetzaltenango, 09001, Guatemala|Saint James's Hospital ( Site 1505), Dublin, D08NHY1, Ireland|Beaumont Hospital ( Site 1506), Dublin, D09 V2N0, Ireland|Tallaght University Hospital ( Site 1513), Dublin, D24 NR0A, Ireland|Soroka University Medical Center ( Site 1603), Beer Sheva, 8410101, Israel|Rambam Health Care Campus ( Site 1606), Haifa, 3109601, Israel|Edith Wolfson Medical Center ( Site 1605), Holon, 5822012, Israel|Hadassah Ein Kerem Medical Center ( Site 1604), Jerusalem, 9112001, Israel|Meir Medical Center ( Site 1609), Kfar-Saba, 4428132, Israel|Rabin Medical Center ( Site 1602), Petah Tikva, 4941492, Israel|Chaim Sheba Medical Center. ( Site 1607), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 1601), Tel Aviv, 6423906, Israel|AUOP Ospedale Santa Chiara ( Site 1100), Pisa, Toscana, 56126, Italy|Humanitas Gavazzeni ( Site 1106), Bergamo, 24125, Italy|Universita Magna Graecia di Catanzaro ( Site 1107), Catanzaro, 88100, Italy|IEO Istituto Europeo di Oncologia ( Site 1105), Milano, 20141, Italy|Azienda Ospedaliero - Universitaria Policlinico di Modena ( Site 1102), Modena, 41124, Italy|A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1103), Napoli, 80131, Italy|Istituto Oncologico Veneto ( Site 1101), Padova, 35128, Italy|Ospedale Civile Spirito Santo ( Site 1104), Pescara, 65100, Italy|Aichi Cancer Center Hospital ( Site 2617), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 2605), Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center ( Site 2615), Matsuyama, Ehime, 791-0280, Japan|Gunma Prefectural Cancer Center ( Site 2602), Ohta, Gunma, 373-8550, Japan|Hyogo Cancer Center ( Site 2619), Akashi, Hyogo, 673-8558, Japan|Kobe City Medical Center General Hospital ( Site 2614), Kobe, Hyogo, 650-0047, Japan|Ibaraki Prefectural Central Hospital ( Site 2611), Kasama, Ibaraki, 309-1793, Japan|Kagawa University Hospital ( Site 2604), Kita-gun, Kagawa, 761-0793, Japan|Kanagawa Cancer Center ( Site 2603), Yokohama, Kanagawa, 241-8515, Japan|Osaki Citizen Hospital ( Site 2626), Osaki, Miyagi, 989-6183, Japan|Kansai Medical University Hospital ( Site 2618), Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital ( Site 2616), Osakasayama, Osaka, 589-8511, Japan|Osaka University Hospital ( Site 2600), Suita, Osaka, 565-0871, Japan|Saitama Cancer Center ( Site 2620), Kitaadachi-gun, Saitama, 362-0806, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 2607), Sunto-gun, Shizuoka, 411-8777, Japan|Tochigi Cancer Center ( Site 2627), Utsunomiya, Tochigi, 320-0834, Japan|Kyorin University Hospital ( Site 2608), Mitaka, Tokyo, 181-8611, Japan|Chiba Cancer Center ( Site 2623), Chiba, 260-8717, Japan|National Hospital Organization Kyushu Cancer Center ( Site 2609), Fukuoka, 811-1395, Japan|Gifu University Hospital ( Site 2621), Gifu, 501-1194, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2625), Hiroshima, 730-8518, Japan|Kumamoto University Hospital ( Site 2601), Kumamoto, 860-8556, Japan|Niigata Cancer Center Hospital ( Site 2622), Niigata, 951-8566, Japan|National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 26, Osaka, 540-0006, Japan|Osaka International Cancer Institute ( Site 2613), Osaka, 541-8567, Japan|Osaka General Medical Center ( Site 2624), Osaka, 558-8558, Japan|National Cancer Center Hospital ( Site 2612), Tokyo, 104-0045, Japan|Toranomon Hospital ( Site 2628), Tokyo, 105-8470, Japan|Tokyo Metropolitan Komagome Hospital ( Site 2606), Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR ( Site 2610), Tokyo, 135-8550, Japan|Seoul National University Hospital ( Site 2703), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2700), Seoul, 03722, Korea, Republic of|Asan Medical Center ( Site 2702), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 2701), Seoul, 06351, Korea, Republic of|Auckland City Hospital ( Site 2300), Auckland, 1023, New Zealand|Uniwersytecki Szpital Kliniczny im. J. M. Radeckiego we Wroclawiu ( Site 1705), Wroclaw, Dolnoslaskie, 50-556, Poland|Dolnoslaskie Centrum Onkologii. ( Site 1712), Wroclaw, Dolnoslaskie, 53-413, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1709), Lublin, Lubelskie, 20-080, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1715), Gdynia, Pomorskie, 81-519, Poland|Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 1708), Koscierzyna, Pomorskie, 83-400, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1710), Bielsko-Biala, Slaskie, 43-300, Poland|Przychodnia Lekarska Komed ( Site 1716), Konin, Wielkopolskie, 62-500, Poland|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1807), Ufa, Baskortostan, Respublika, 450054, Russian Federation|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1815), Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation|Podolsky City Clinical Hospital ( Site 1817), Podolsk, Moskovskaya Oblast, 142110, Russian Federation|Blokhin National Medical Oncology ( Site 1805), Moscow, Moskva, 115478, Russian Federation|Medical University REAVIZ ( Site 1816), Samara, Samarskaya Oblast, 443011, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1801), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|St Petersburg City Clinical Oncology Dispensary ( Site 1812), Saint Petersburg, Sankt-Peterburg, 198255, Russian Federation|Leningrad Regional Oncology Center ( Site 1800), Saint-Petersburg, Sankt-Peterburg, 188663, Russian Federation|Hospital General Universitario de Elche ( Site 1404), Elche, Alicante, 03203, Spain|Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, 33011, Spain|Hospital Germans Trias i Pujol. ICO de Badalona ( Site 1410), Badalona, Barcelona, 08916, Spain|Hospital Universitario Marques de Valdecilla ( Site 1405), Santander, Cantabria, 39008, Spain|Hospital Universitario Quiron Madrid ( Site 1407), Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital General Universitari Vall d Hebron ( Site 1401), Barcelona, 08035, Spain|Hospital Universitario Ramon y Cajal ( Site 1400), Madrid, 28034, Spain|Adana Sehir Hastanesi ( Site 2002), Adana, 01370, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2017), Ankara, 06100, Turkey|Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006), Ankara, 06200, Turkey|Trakya Universitesi Tip Fakultesi ( Site 2015), Edirne, 22030, Turkey|Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000), Erzurum, 25240, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001), Istanbul, 34098, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011), Izmir, 35340, Turkey|Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009), Malatya, 44280, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012), Sakarya, 54290, Turkey|City Clinical Hosp.4 of DCC ( Site 2102), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2101), Kryviy Rih, Dnipropetrovska Oblast, 50048, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2105), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76018, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 2112), Kharkiv, Kharkivska Oblast, 61070, Ukraine|Medical Center Asklepion LLC ( Site 2115), Khodosivka, Kyivska Oblast, 08173, Ukraine|Clinic of National Cancer Institute ( Site 2104), Kyiv, Kyivska Oblast, 03022, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2114), Kyiv, Kyivska Oblast, 03126, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2106), Lviv, Lvivska Oblast, 79031, Ukraine|MI Odessa Regional Oncological Centre ( Site 2108), Odesa, Odeska Oblast, 65055, Ukraine|Medical Centre LLC Oncolife ( Site 2103), Zaporizhzhya, Zaporizka Oblast, 69104, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2110), Kyiv, 03115, Ukraine|Royal Hospital in Derby ( Site 1514), Derby, Derbyshire, DE22 3NE, United Kingdom|Ninewells Hospital and Medical School ( Site 1504), Dundee, Dundee City, DD1 9SY, United Kingdom|Castle Hill Hospital ( Site 1501), Cottingham, East Riding Of Yorkshire, HU16 5JQ, United Kingdom|University College London Hospital NHS Foundation Trust ( Site 1508), London, London, City Of, NW1 2PG, United Kingdom|St Georges University Hospitals NHS Foundation Trust. ( Site 1500), London, London, City Of, SW17 0QT, United Kingdom|Royal Marsden Hospital ( Site 1510), Sutton, Surrey, SM2 5PT, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 1512), London, SW3 6JJ, United Kingdom|The Christie Hospital NHS Foundation Trust ( Site 1503), Manchester, M20 4BX, United Kingdom|Mount Vernon Cancer Centre ( Site 1507), Northwood, HA6 2RN, United Kingdom|Manor Hospital Walsall England ( Site 1515), Walsall, WS2 9PS, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/26/NCT03615326/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/26/NCT03615326/SAP_001.pdf"
